Last update 01 Nov 2024

Nippon Medical School Hospital

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Nippon Medical School Hospital

JPRN-UMIN000051643 / CompletedIIT

Skin Patch testing of skin and hair care products to the normal volunteer. - Skin Patch testing of skin and hair care products to the normal volunteer.

Start Date03 Feb 2023

Sponsor / Collaborator

Nippon Medical School Hospital

JPRN-UMIN000044467 / RecruitingIIT

Phase I study for feasibility of less-invasive laparoscopic endoscopic cooperative surgery - Phase I study for feasibility of less-invasive laparoscopic endoscopic cooperative surgery

Start Date16 Jul 2021

Sponsor / Collaborator

Nippon Medical School Hospital

JPRN-UMIN000039815 / CompletedIIT

Prediction of lymph node metastasis in early colorectal cancer by liquid biopsy - Prediction of lymph node metastasis in early colorectal cancer by liquid biopsy

Start Date03 Jun 2020

Sponsor / Collaborator

Nippon Medical School Hospital

100 Clinical Results associated with Nippon Medical School Hospital

0 Patents (Medical) associated with Nippon Medical School Hospital

1,078

Literatures (Medical) associated with Nippon Medical School Hospital

27 Oct 2024·Journal of Plastic and Reconstructive Surgery

The First National Survey of Endoscopic Plastic Surgery by the Japan Society of Plastic and Reconstructive Surgery 2020-2021

Author: Dogo, Kyoko ; Ono, Shimpei ; Kadota, Hideki ; Hashikawa, Kazunobu ; Inoue, Yoshikazu ; Satake, Toshihiko ; Miyamoto, Shimpei ; Kashimura, Tsutomu ; Uemura, Tetsuji ; Asano, Yuko ; Yano, Tomoyuki

01 Oct 2024·Hepatology International

Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma

Article

Author: Hiraoka, Atsushi ; Tada, Toshifumi ; Okubo, Tomomi ; Hidaka, Hisashi ; Atsukawa, Masanori ; Itokawa, Norio ; Iwasaki, Shuichiro ; Koshiyama, Yuichi ; Arase, Yoshitake ; Tsuruya, Kota ; Maeda, Shin ; Nozaki, Akito ; Uojima, Haruki ; Chuma, Makoto ; Sugimori, Makoto ; Miura, Yuki ; Morimoto, Manabu ; Kagawa, Tatehiro ; Yasuda, Satoshi ; Kumada, Takashi ; Numata, Kazushi ; Kusano, Chika ; Toyoda, Hidenori ; Mishima, Yusuke ; Tokoro, Chikako

BACKGROUNDThe aims of this study were to identify clinically significant biomarkers of a response to atezolizumab plus bevacizumab (ATZ + BV) therapy and to develop target strategies against unresectable hepatocellular carcinoma (u-HCC).METHODWe first investigated the potential of circulating tumor DNA (ctDNA) to serve as a biomarker for predicting the therapeutic outcome in 24 u-HCC patients treated with ATZ + BV therapy. Next, we analyzed levels of immune-related cytokines in blood samples from 134 u-HCC patients who received ATZ + BV. For this, serum immune-related molecules or cancer-immune cycle-related molecules that have been reported in HCC patient sera, namely CD274, LAG-3, CCL2, 4, 5, CXCL1, 9, 10, 12, 13, CX3CL1, CCR5, IFNγ and IL-6, 8 were measured using enzyme-linked immunosorbent assay.RESULTSMore than 1% of variant read frequency (VRF) mutations were found in TP53, APC, PIK3CA and VHL, although with no correlation with treatment response. Among the 15 cytokines evaluated, CXCL9 and LAG-3 levels were significantly different between patients with objective response (OR), stable disease (SD), and progressive disease (PD) following ATZ + BV treatment. Receiver-operating characteristic curve analyses of CXCL9 (cut-off value: 419.1 pg/ml) and LAG-3 (cut-off value: 3736.3 pg/ml) indicated areas of 0.779 and 0.697, respectively, for differentiating PD from non-PD and OR from non-OR. In multivariate analysis of progression-free survival (PFS) and overall survival (OS), high serum CXCL9 (hazard ratio (HR) and 95% confidence interval (CI): 0.412 (0.251-0.677) (p = 0.0005) for PFS and 0.252 (0.125-0.508) (p = 0.0001) for OS), and low serum LAG-3 (HR and 95% CI 0.419 (0.249-0.705) (p = 0.0011) for PFS and 0.294 (0.140-0.617) (p = 0.0012) for OS) were independent positive predictive factors.CONCLUSIONAlthough, as far as we examined, no ctDNA mutations in blood were found to be related to ATZ + BV treatment efficacy, serum CXCL9 and LAG-3 levels, which are related to the cancer-immune cycle, were associated with treatment efficacy and could be predictive markers of the efficacy of ATZ + BV treatment in HCC patients.

25 Sep 2024·Circulation Journal

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Japanese Patients With Venous Thromboembolism　― The Primary Results From the KUROSIO Study ―

Article

Author: Yuzaki, Mitsuru ; Obayashi, Toru ; Nishimura, Yuki ; Umetsu, Michihisa ; Yamada, Norikazu ; Nakamura, Masato ; Ogura, Toru ; Nakamura, Mashio ; Tsujita, Kenichi ; Yamamoto, Takeshi ; Watanabe, Atsuyuki ; Satokawa, Hirono ; Tamaru, Satoshi

BACKGROUNDDirect oral anticoagulants (DOACs) are recommended as the first-choice anticoagulation therapy in the acute phase of venous thromboembolism (VTE). However, there is limited real-world data for Japanese VTE patients.METHODS AND RESULTSThe KUROSIO study (UMIN000023747) was a prospective long-term observational study comprising 1,017 patients with concurrent acute symptomatic pulmonary thromboembolism and proximal deep vein thrombosis (DVT) or isolated calf DVT initially treated with DOACs. After excluding 24 patients, 993 (mean age, 66.3±15.1 years; 58.6% females) were analyzed. The incidences of recurrent symptomatic VTE and major bleeding for up to 52 weeks after diagnosis were 3.2% and 2.2%, respectively. Multivariate analyses revealed chemotherapy and anemia as significant risk factors associated with recurrent symptomatic VTE and major bleeding, respectively.CONCLUSIONSThe efficacy and safety of DOACs in Japanese patients with VTE were determined in this real-world observational study.

100 Deals associated with Nippon Medical School Hospital

100 Translational Medicine associated with Nippon Medical School Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nippon Medical School Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing